Submitted on Saturday 17th July 2021
Rejected on Wednesday 21st July 2021
Current status: Rejected
Rejection code: irrelevant (see below for details)
Get approval of Sacituzumab Govitecan (Trodelvy) for mTNBC for UK patients.
MHRA application for Trodelvy was made in January 2021, via Project Orbis, a system that the government promised would deliver rapid access to cutting edge cancer treatments, post Brexit. Trodelvy was approved by FDA in the USA, April 2020. Current timelines suggest UK patients will wait till 2022.
Of all the breast cancers, metastatic Triple Negative Breast Cancer (mTNBC) is the hardest to treat with the worst prognosis. The average life expectancy is 12-18 months. Trodelvy can work to shrink cancer in patients who are otherwise resistant to chemotherapy. In the UK every year, around 1650 women die of metastatic TNBC, post co-vid these figures are likely to be double.
You can't sign this petition because it was rejected. But you can still comment on it here at Repetition.me!
The Government e-Petitions Team gave the following reason:
We can't accept your petition because the UK Government and Parliament aren't responsible for the issue you raise.
Decisions about which medicines can be offered to patients on the NHS are made by the Medicines and Healthcare Products Regulatory Authority and the National Institute for Health and Care Excellence. Both of these bodies are operationally independent of the UK Government and Parliament.
18.227.190.93 Tue, 07 May 2024 06:45:02 +0100
